Trough Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the relative bronchoprotection (at trough)
conferred by 2-week chronic dosing with levosalbutamol and racemic salbutamol in mild to
moderate asthmatics. Patients will be preselected into two groups on the basis of their
beta-2 adrenoreceptor polymorphisms. The investigators will evaluate if this has a
differential effect on the bronchoprotection conferred by both formulations of salbutamol, as
evidenced by a rebound in airway hyper-responsiveness, in order to determine whether any
effect can be explained by the S enantiomer in the racemic formulation.